Study medicine LBS-007 for relapsed leukemia patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests how safe and tolerable LBS-007 is for adults with AML or ALL that has come back or is resistant to treatment. It may help people who can’t use standard therapies or have no proven treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You have confirmed AML or ALL that has relapsed or not responded to treatment.
- You either can’t get standard treatment expected to control the leukemia long-term, or you don’t have other proven options.
- Your daily function is good enough: ECOG score 0 to 2 (can do most normal activities, with limited limitations).
- You are not receiving chemotherapy, radiation, or immunotherapy at the same time.
- You are able to understand the study and follow its rules (can give informed consent).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This study tests an experimental drug called TCB008 given through an IV. It is for people with acute myeloid leukemia (AML) or a related condition called MDS/AML that has come back or not gone away after prior treatment. The goal is to see if the drug is safe and if it helps.
This trial tests a new treatment, BG1805, for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It targets a specific marker on leukemia cells called CLL-1.
This trial tests an experimental treatment called BG1805 for children with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. BG1805 is a type of cell therapy (like CAR-T) that targets the CLL-1 marker on leukemia cells, potentially helping the body fight the cancer.
This Phase 1 study tests BXCL701 in adults whose acute myeloid leukemia (AML) or high-blast myelodysplastic syndrome (MDS-EB-2) has come back or not responded to prior treatment. The goal is to find a safe dose and see how the treatment affects cancer cells.
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Hear when a new Relapsed or Resistant Acute Leukaemias trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.